Background: An increasing understanding of the genes and molecular pathways of glioblastoma multiforme (GBM) can provide us a useful insight for the development of more effective targeted therapeutic. Methods: To investigate the expression and clinical significance of miR-299 and its target genes in GBM, the expression levels of miR-299 and its target gene in human normal brain tissues and GBM were analyzed in silico using genes microarray and hierarchical clustering analysis followed by validation with quantitative RT-PCR. Results: Our results show that miR-299 is up-regulated in GBM patients. Moreover, patients with low miR-299 expression had longer overall survival (OS) compared with those with high miR-299 expression. RNA polymerase II elongation factor, ELL2, was identified as a miR-299 direct target. High expression of ELL2 together with miR-299 down-regulation correlated with a shorter median OS. Conclusions: Our results provide the first evidence that ELL2 is a direct target of miR-299 and increased ELL2 expression and down-regulation of miR-299 are associated with GBM progression and poor prognosis in patients, suggesting that ELL2 and miR-299 might have potential prognostic value and be used as tumor biomarkers for the diagnosis of patients with GBM.
Introduction
Glioblastoma multiforme (GBM), also called glioblastoma or grade IV astrocytoma, is a molecularly heterogeneous malignancy, which is the most common glioma, accounting for 45.2% of malignant primary CNS tumors, 54% of all gliomas and 16% of all primary CNS tumors (1) . The World Health Organization (WHO) divides gliomas into four grades with increasing aggressive, of which glioblastoma is classified as grade IV, the most malignant and fatal one (2) . GBM is considered incurable currently, as even following the standard-of-care treatment strategies including maximal safe resection, followed by 6 weeks of radiation and concurrent daily temozolomide (TMZ) chemotherapy, followed by at least 6 months of adjuvant TMZ , the median survival is still as short as 15 months (3, 4) . The poor prognosis is attributed to therapeutic resistance and tumor recurrence caused by its infiltrative growth pattern.
To break through current therapeutic challenges and improve the prognosis of GBM, novel therapies such as molecular targeted therapy, immunotherapy, gene therapy, stem cell-based therapies, targeting of drug repositioning (DR) (5) and autophagic regulatory circuitry (6) have emerged, of which molecular targeted therapy is the most promising therapy as seen successes of 'personalized' and targeted therapies in other cancer types, such as non-small cell lung cancer (7) and melanoma (8) . Similarly, an increasing understanding of the genes and molecular pathways of GBM can provide us a useful insight for the development of more effective targeted therapeutic. Some molecular targeted drugs have been in clinical trials, and more potential targets are under study (9) . Several identified significantly mutated genes in the glioblastoma represent direct targets of an FDA-approved therapy (epidermal growth factor receptor (EGFR), PDGFRA and BRAF). However, biomarkers that are sensitive and specific enough to assess the response to therapy and prognosis are lacking in GBM.
MicroRNAs (miRNAs) are small double-stranded, non-protein coding RNAs, 21-25 nucleotides in length that function in RNA silencing and post-transcriptional regulation of gene expression. They can play an important role in cell proliferation, differentiation and apoptosis (10) . The dysregulation of certain miRNAs (oncomiRs) are associated with specific cancer forming (oncogenic) events, and many different oncomirs have been identified in numerous types of human cancers (11) . Besides, another important role of miRNAs in cancer is prediction of outcome according to their expression level.
More and more researches show that some miRNAs and genes participate in the progression of GBM (12) (13) (14) (15) (16) . As it is reported that miR-124 functions as a tumor suppressor by targeting hCLOCK1 in GBM (17) . MiR-126 regulates the ERK pathway via targeting KRAS to inhibit the glioma cell proliferation and invasion (18) and miR-224-3p inhibits hypoxia-induced autophagy by targeting autophagy-related genes in human glioblastoma cells (19) .
Yet, there is no previous report about the expression level and prognosis value of miR-299 and its target genes in GBM. Thus, in this study, we analyzed miRNAs and genes expression using gene microarray to identify their differential expression in GBM and normal brain tissues, and then explore the correlation between miR-299 and its target gene ELL2 by luciferase reporter assays and qRT-PCR. We hope it can provide us a useful insight for the development of more effective targeted therapy in GBM.
Materials and methods

Ethics statement
The study protocol and acquisition of tissue specimens were approved by the Ethical Committee of Ganzhou City People's Hospital (2015-RES-10). Each participant provided written informed consent before participating in this study.
Acquisition of clinical specimens
Fresh GBM samples were collected from patients undergoing surgical resection and classified according to the last WHO classification of central nervous tumors and clinical histories recorded, which was confirmed by two experienced pathologists independently.
RNA extraction
According to the manufacturer's guideline, total RNA was isolated using Trizol regent (Invitrogen, Carlsbad, CA). RNA quantity was determined using NanoDrop ND-1000 spectrophotometer and the integrity of RNA was measured by gel electrophoresis.
Gene microarray analysis
For gene expression microarray analysis, tumor tissue from 22 GBM patients was assessed on an Affymetrix Array platform (Santa Clara, CA). The sample preparation and microarray hybridization were performed based on the manufacturer's standard protocols and the published paper (20) (21) (22) .
Cell lines and transfection
Human glioblastoma cell line U251 were purchased from Shanghai Institute for Biological Sciences (Shanghai, China) and cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, USA) supplemented with 10% fetal bovine serum (FBS; HyClone, USA), 100 units/ml penicillin and 100 mg/ml streptomycin at 37°C in a humidified chamber supplemented with 5% CO 2 .
MiR-299 mimic, miR-299 inhibitor and corresponding negative control miRNA (miR-NC) were purchased from Shanghai GenePharma (Shanghai, China). These molecular productions were transiently transfected into U251 cells, respectively, using Oligofectamine Transfection Reagent (Invitrogen) according to the manufacturer's instructions.
Reporter assays
The human ELL2 3' UTR oligonucleotides containing the wild-type (Wt) or mutant (Mut) miR-299 binding site were subcloned into the XhoI and NotI sites of the psiCHECK2 vector (Promega, Madison, WI). For luciferase assay, U251 cells were inoculated into 24-well plates and cultured for 24 h; then, cells were co-transfected with the Wt/Mut reporter plasmid (100 ng) and miR-299 mimic/miR-NC/miR-299 inhibitor (100 nM). Forty-eight hours after transfection, luciferase assay was determined using the Dual-Luciferase kit (Promega, Madison, WI).
Quantitative RT-PCR (qRT-PCR)
For qRT-PCR of ELL2, cDNA was synthesized from total RNA (10 ng), and quantitative PCR reactions were performed with the Taqman Universal PCR Kit (Life Technologies). GAPDH was used as the internal control.
Quantitative qRT-PCR for miR-299 was performed using the Taqman universal PCR Kit (Life Technologies; Grand Island, NY, USA). U6 small nuclear RNA was used as internal control and the 2 -ΔΔCT method was used to analyze the expression levels of miR-299 and ELL2.
Bioinformatic analysis
The expression levels of miRNAs were investigated in four GBM cell lines (SF-268, SF-295, SNB-19 and U251) and other cancer cell using the NCI-60 dataset (https://discover.nci.nih.gov/cellminer/). Hierarchical clustering was performed using the multiple experiment viewer (MeV) 4.7.1 software (http://www.tm4.org/mev/). Each row represents a miRNA or gene, and each column represents a sample in the heat map diagram. The clustering trees of miRNA or gene are shown on the left, and the sample clustering tree appears at the top. We used three target gene prediction software DIANA-TarBase (21), Targetscan (http://www.targetscan.org) and miRDB (http://mirdb. org/miRDB/) to forecast several potential target genes of miR-299.
Statistical analysis
The results were expressed as mean ± standard deviation (SD). Statistical significance between the groups was assessed by using oneway analysis of variance (ANOVA). Univariate survival analysis and multivariate analyses were carried out using the Kaplan-Meier method. Spearman's correlation coefficient was used to test the relationship of expression level between miR-299 and ELL2. All calculations were performed with the SPSS 20.0 software program (SPSS Inc, Chicago, IL, USA). The level of significance was chosen as P < 0.05.
Results
MiRNAs microarray analysis
In order to analysis specific dysregulated miRNAs in GBM cell, we download one group of raw data from NCI-60 dataset (RNA_ Agilent_Human_microRNA_(V2)_GeneSpringGX). After hierarchical clustering for differential miRNAs in four GBM cell lines (SF-268, SF-295, SNB-19, U251) comparing with other tumor cells, 38 miRNAs displayed at least a 2-fold increased or 0.5-fold decreased in expression at the P < 0.01 level with a false discovery rate (Fig. 1A , Table S1 ).
Meanwhile, we download another group of miRNAs microarray dataset (RNA__microRNA_OSU_V3_chip_log2) from NCI-60 dataset. The data were clustered analysis with MEV4.7.1 software as above. Seven miRNAs displayed at least a 2-fold increased or 0.5-fold decreased in expression at the P < 0.01 level with a false discovery rate (Fig. 1B, Table S2 ).
Two miRNAs were found to be dysregulated in both miRNAs microarrays, one is miR-200b/c which has been abundantly reported in neoplasm, and the other is unreported miR-299 which is associated to GBM.
The expression of miR-299 in GBM
Subsequently, we analyzed the expression level of miR-299 in 94 normal controls and 446 various cancers included 20 GBM from GEO datasets (GSE61741). This project analyzed peripheral blood miRNAs profiles and each miRNA had been measured in at least seven replicates which the median of the replica had been computed. The results showed that the expression level of miR-299 in GBM was significantly higher than in normal (P < 0.01, Fold change = 1.88, Fig. 2A) .
Then, we, respectively, download three paired GBM tissues vs. normal tissues derived from GEO datasets (GSE65626), four paired GBM tissues vs. peritumoral tissues derived from GEO datasets (GSE61710) and 82 GBM tissues vs. five normal tissues derived from GEO datasets (GSE25631) to evaluate the expression level of miR-299. Results from GEO datasets GSE65626 (P = 0.02, Fold change = 1.64, Fig. 2B ), GSE61710 (P = 0.045, Fold change = 1.55, Fig. 2C ) and GSE25631 (P = 0.023, Fold change = 2.94, Fig. 2D ) all show that miR-299 expression was remarkably up-regulated in GBM compared with normal tissues and peritumoral tissues.
To determine the prognostic value of miR-299 expression in GBM, we used Kaplan-Meier survival analysis to link miR-299 expression with OS. Our results showed that high miR-299 expression correlated with worsened overall survival (OS), whereas low miR-299 mRNA levels were associated with increased OS. Thus, miR-299 expression was significantly associated with decreased OS (P = 0.036) in GBM patients (Fig. 2E) .
Gene microarray analysis
We download GSE4412 dataset from GEO database, and gene expression profile were clustered analysis in 59 GBM samples (including 13 GBM with good prognosis and 46 GBM with poor prognosis) from Affymetrix Human Genome U133A Array and in another 59 GBM samples (also including 13 GBM with good prognosis and 46 GBM with poor prognosis) from Affymetrix Human Genome U133B Array.
Of all the genes represented therein, 893 genes displayed in the first array and 1198 displayed in the second array at a 1.5-fold in expression at the P < 0.05 level. There were 81 common differential genes in the two arrays, of which, 18 genes represent down-regulated function. Hierarchical clustering analysis was used to detect the expression profile of 81 differential genes (Fig. 3A) and 18 downregulated genes (Fig. 3B ) (Fold change ≥2 or ≤0.5; P < 0.05) in 59 GBM.
Then we further analyzed our previous gene microarray datasets of 22 cases of GBM which included 12 GBM with good prognosis and 10 GBM with poor prognosis (Fold change > 3; P < 0.01; Fig. 3C ), of which down-regulated ELL2 and up-regulated FGF18, GBP1 were in common with the 81 differential genes.
Prediction of target genes of miRNA-299
To elucidate whether there were paired miRNAs and target mRNAs aberrantly expression profiles in GBM, we used three target gene prediction software, including DIANA-TarBase, Targetscan and miRDB, to search potential target genes of miR-299. There were 742, 298 and 204 predicted target genes of miR-299 in DIANA-TarBase, Targetscan Figure 2 . The expression of miR-299 in GBM. A, Expression levels of miR-299 in normal tissues and various cancers derived from the GEO dataset (GSE61741). B, Expression levels of three paired GBM tissues vs. normal tissues derived from GEO dataset (GSE65626). C, Expression levels of four paired GBM tissues vs. peritumoral tissues derived from GEO dataset (GSE61710). D, Expression levels of 82 GBM tissues vs. five normal tissues derived from GEO dataset (GSE25631). E, Univariate survival analysis of OS in 22 GBM as determined by Kaplan-Meier plots estimates based on miR-299 expression. and miRDB, respectively (Fig. 4A) . Based on the analysis of the three softwares, we found 50 common target genes.
Combining with the previous studies of gene microarray analysis, we found that ELL2 was the only one common differential gene among 50 predicted target genes, 81 dysregulated genes in 118 GBMs and 18 dysregulated genes in 22 GBMs (Fig. 4B) .
Validation of miR-299/mRNAs expression and correlation using qRT-PCR
To further verify the correlation between miR-299 and ELL2, we extracted RNA from 36 fresh GBM samples and carried out qRT-PCR. Next we analyzed the correlation of miR-299 and ELL2 gene in 36 GBM samples and found that the relative expression level between miR-299 and ELL2 presented inverse correlation with a Spearman's correlation coefficient of 0.65 (Fig. 4C) .
Identification of ELL2 as miR-299 direct target in U251 cells
To confirm predicted target gene ELL2 as direct target of miR-299, we performed ELL2 mRNA level change in U251 cells treated with miR-299 mimic or inhibitor. Results showed that transfection of miR-299 mimic caused a significant decrease in ELL2 mRNA level compared with transfection of miR-NC in U251 cells, while transfected with miR-299 inhibitor showed a significant increase of ELL2 mRNA levels than control group (Fig. 4D) .
To further confirm ELL2 as a direct target of miR-299, we performed luciferase reporter assays in U251 cells. As shown in Fig. 4E , transfection of miR-299 mimic caused a significant decrease in luciferase activity in cells transfected with the reporter plasmid with wild-type targeting sequence of mRNA, but not reporter plasmid with mutant sequence of ELL2 gene.
Clinical significance of ELL2 and miR-299 in GBM
Moreover, we studied the prognostic value of miR-299 together with ELL2 expression in 36 GBM samples. Multivariate analysis of OS by Kaplan-Meier survival analysis indicated that GBM patients with high miR-299 expression and down-regulation ELL2 had significantly decreased OS (P = 0.002) (Fig. 4F) , suggesting that ELL2 and miR-299 might have potential prognostic value and be used as tumor biomarkers for the diagnosis of patients with GBM.
Discussion
GBM is the most common and aggressive primary central nervous system malignancy with a median survival of 15 months. So far, numerous signaling pathways in malignant glioma pathogenesis including receptor tyrosine kinase (RTK)/RAS/phosphatidylinositol 3-kinase (PI3K), p53, and retinoblastoma protein (RB) signaling pathways and proangiogenic pathway have been identified (3) . Thus, these signaling pathways provide potential molecular therapy targeting of glioblastoma. Whole-exome sequencing analysis from TCGA identified several significantly mutated genes, such as EGFR, PDGFRA, PIK3CA, PTEN, NF1, RB1, TP53, etc. (23), of which amplification and/or mutation of the EGFR gene were found in up to 60% of primary GBM cases (24) . Despite the accumulated knowledge on the molecular changes, these findings have not have be significantly translated into improved outcomes for GBM patients.
A large number of studies have demonstrated that miRNAs are involved in the development of malignant glioma and might be of diagnostic or prognostic value (25) . However, the correlation of miR-299 and GBM has not been reported.
In present study, after hierarchical clustering analysis of two groups of miRNA microarray data from NCI-60 dataset, we found two common dysregulated miRNAs in two groups, in which miR200b/c is reported to be involved in the onset and progression of cancer, but there is unreported about miR-299 related to cancer. Then, we analyzed the expression levels of miR-299 in normal tissues and various cancers, results showed that miR-299 was significantly up-regulated in GBM patient. We further compared the expression levels of miR-299 in GBM and normal tissue and it showed that miR-299 expression was remarkably up-regulated in GBM compared with normal tissues and peritumoral tissues. Univariate survival analysis of OS in 22 GBM showed that high level of miR-299 is correlated with a shorter median OS in GBM. Thus, miR-299 might be a potential prognostic factor in GBM.
Subsequently, the hierarchical clustering analysis of three groups of microarray data demonstrated three common differential genes in GBM, including down-regulated ELL2, up-regulated FGF18 and GBP1. Afterwards, ELL2 was indicated to be the target genes of miR-299 by three target gene prediction software including DIANATarBase, Targetscan and miRDB and was further validated by luciferase reporter assays. Our results further showed that expression of miR-299 was negatively correlated with mRNA levels of ELL2 gene. What's more, multivariate analysis of OS with a Cox proportional hazards model in GBM based on miR-299 and ELL2 expression demonstrated that the high expression of miRNA-299 accompanied with low expression of ELL2 indicated a poor outcome in GBM. ELL2 is a member of an ELL family of RNA polymerase II elongation factors located at 5q15, which is the homologous to the product of the human ELL gene, but may perform gene-or tissuespecific functions instead of performing completely general functions (26) . Recent studies have shown that ELL functions as an E3 ubiquitin ligase and targets c-Myc for proteasomal degradation and may be as an potential tumor suppressor, whose mutation not only loses the ability to inhibit cell proliferation and xenograft tumor growth, but also promotes tumor metastasis (27) . It also had been reported that there exists a mutually inhibitory interaction between p53 and a general transcription elongation factor ELL (28) . However, there is no previous report about the role of ELL2 in cancer, so the role and molecular mechanisms behind low-regulation of ELL2 requires further investigation.
In short, we have demonstrated that miRNA-299 is up-regulated while its target gene ELL2 is down-regulated in GBM. What's more, our research indicated that high expression of miRNA-299 accompanied with low expression of ELL2 indicated a poor outcome in GBM, which means that they might be as predictive markers in GBM patients.
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